Literature DB >> 30209692

Is There Still a Role for Digoxin in the Management of Atrial Fibrillation?

Jeffrey B Washam1, Manesh R Patel2.   

Abstract

PURPOSE OF REVIEW: A number of recent observational analyses have assessed clinical outcomes associated with digoxin use in patients with atrial fibrillation. In this review, we review these data and provide suggestions on the contemporary use of digoxin in patients with atrial fibrillation as supported by the recent evidence. RECENT
FINDINGS: Observational data from clinical trials and registries have provided variable results on the safety and efficacy of chronic digoxin use in patients with atrial fibrillation. In general, results have been consistent with an associated increase in adverse clinical outcomes with digoxin use in atrial fibrillation patients without heart failure. In atrial fibrillation patients with heart failure, while the weight of evidence suggested an associated risk with digoxin therapy, the results are inconsistent. In patients with atrial fibrillation without heart failure, digoxin should generally be avoided. In atrial fibrillation patients with heart failure, digoxin should generally be reserved for patients that do not achieve adequate rate control or are not tolerant of other rate control therapies.

Entities:  

Keywords:  Atrial fibrillation; Digoxin

Mesh:

Substances:

Year:  2018        PMID: 30209692     DOI: 10.1007/s11886-018-1047-y

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  24 in total

Review 1.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2014-03-28       Impact factor: 24.094

2.  Digoxin and Mortality in Patients With Atrial Fibrillation.

Authors:  Renato D Lopes; Roberto Rordorf; Gaetano M De Ferrari; Sergio Leonardi; Laine Thomas; Daniel M Wojdyla; Peter Ridefelt; John H Lawrence; Raffaele De Caterina; Dragos Vinereanu; Michael Hanna; Greg Flaker; Sana M Al-Khatib; Stefan H Hohnloser; John H Alexander; Christopher B Granger; Lars Wallentin
Journal:  J Am Coll Cardiol       Date:  2018-03-13       Impact factor: 24.094

3.  Digoxin in patients with permanent atrial fibrillation: data from the RACE II study.

Authors:  Bart A Mulder; Dirk J Van Veldhuisen; Harry J G M Crijns; Jan G P Tijssen; Hans L Hillege; Marco Alings; Michiel Rienstra; Maarten P Van den Berg; Isabelle C Van Gelder
Journal:  Heart Rhythm       Date:  2014-06-09       Impact factor: 6.343

4.  Interaction between digoxin and dronedarone in the PALLAS trial.

Authors:  Stefan H Hohnloser; Jonathan L Halperin; A John Camm; Peggy Gao; David Radzik; Stuart J Connolly
Journal:  Circ Arrhythm Electrophysiol       Date:  2014-11-06

5.  Digoxin and risk of death in adults with atrial fibrillation: the ATRIA-CVRN study.

Authors:  James V Freeman; Kristi Reynolds; Margaret Fang; Natalia Udaltsova; Anthony Steimle; Niela K Pomernacki; Leila H Borowsky; Teresa N Harrison; Daniel E Singer; Alan S Go
Journal:  Circ Arrhythm Electrophysiol       Date:  2014-11-20

6.  Rate-control treatment and mortality in atrial fibrillation.

Authors:  Tze-Fan Chao; Chia-Jen Liu; Ta-Chuan Tuan; Su-Jung Chen; Kang-Ling Wang; Yenn-Jiang Lin; Shih-Lin Chang; Li-Wei Lo; Yu-Feng Hu; Tzeng-Ji Chen; Chern-En Chiang; Shih-Ann Chen
Journal:  Circulation       Date:  2015-09-17       Impact factor: 29.690

7.  Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data.

Authors:  K Gjesdal; J Feyzi; S B Olsson
Journal:  Heart       Date:  2007-05-04       Impact factor: 5.994

Review 8.  Systematic review and meta-analysis of mortality and digoxin use in atrial fibrillation.

Authors:  Waqas Qureshi; Wesley T O'Neal; Elsayed Z Soliman; Mouaz H Al-Mallah
Journal:  Cardiol J       Date:  2016-04-11       Impact factor: 2.737

9.  Digoxin and mortality in atrial fibrillation: a prospective cohort study.

Authors:  Pär Hallberg; Johan Lindbäck; Bertil Lindahl; Ulf Stenestrand; Håkan Melhus
Journal:  Eur J Clin Pharmacol       Date:  2007-08-08       Impact factor: 2.953

10.  Edoxaban versus warfarin in patients with atrial fibrillation.

Authors:  Robert P Giugliano; Christian T Ruff; Eugene Braunwald; Sabina A Murphy; Stephen D Wiviott; Jonathan L Halperin; Albert L Waldo; Michael D Ezekowitz; Jeffrey I Weitz; Jindřich Špinar; Witold Ruzyllo; Mikhail Ruda; Yukihiro Koretsune; Joshua Betcher; Minggao Shi; Laura T Grip; Shirali P Patel; Indravadan Patel; James J Hanyok; Michele Mercuri; Elliott M Antman
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245

View more
  1 in total

1.  Identification and characterization of Cardiac Glycosides as senolytic compounds.

Authors:  Francisco Triana-Martínez; Pilar Picallos-Rabina; Sabela Da Silva-Álvarez; Federico Pietrocola; Susana Llanos; Verónica Rodilla; Enrica Soprano; Pablo Pedrosa; Alba Ferreirós; Marta Barradas; Fernanda Hernández-González; Marta Lalinde; Neus Prats; Cristina Bernadó; Patricia González; María Gómez; Maria P Ikonomopoulou; Pablo J Fernández-Marcos; Tomás García-Caballero; Pablo Del Pino; Joaquín Arribas; Anxo Vidal; Miguel González-Barcia; Manuel Serrano; María I Loza; Eduardo Domínguez; Manuel Collado
Journal:  Nat Commun       Date:  2019-10-21       Impact factor: 14.919

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.